Brickell posts $5M loss as it prepares for critical Phase III drug trial later this year

BOULDER — Brickell Biotech Inc. (Nasdaq: BBI) reported a net loss of just over $5 million as it prepares to start final clinical trials for its flagship anti-sweating treatment in the U.S.

The Boulder company reported $600,000 in revenue last quarter compared to $2.6 million in the same period last year, with the drop being attributed to a slowdown in payments from Japanese development partner Kaken Pharmaceutical Co. Ltd.

It reported an overall net loss of $5.1 million for the period.

SPONSORED CONTENT

Commercial Solar is a big investment, but not an overwhelming one

Solar offers a significant economic benefit for commercial property owners while also positively impacting the environment and offering a path to compliance for new municipal requirements like Energize Denver. A local, experienced solar installer will help you navigate the complexities of commercial solar to achieve financial success for your project.

Brickell’s main product is Sofpironium Bromide, a treatment for excessive sweating. The company reported positive results on its Phase III clinical trial in Japan in June.

Brickell and Kaken expect a regulatory decision for sale in Japan within the fourth quarter of this year, along with a Phase III trial for U.S. patients around the same time.

The company raised $18.7 million from new stock sales on the heels of that announcement.

© 2020 BizWest Media LLC